TINAVI

TINAVI Medical Technologies Co., Ltd. (Stock Code: 688277; hereinafter referred to as "TINAVI") is a high-tech enterprise specializing in the independent innovation, large-scale production, professional marketing, and high-quality clinical application of orthopedic surgical robots and related technologies. It is also the first company in China and the fifth globally to obtain a medical robot registration license. In 2020, TINAVI successfully went public on the STAR Market IPO. As a pioneer of medical robotics in China, TINAVI has obtained more than 100 patents and is a member of the "National Robot Standardization Overall Group," the supporting unit of the "National-Local Joint Engineering Research Center for Medical Robots," and the supporting unit of the "Beijing Medical Robotics Industry Innovation Center." TINAVI is also a council member of the China Association of Medical Equipment, a vice-chairman unit of the Medical Robotics Engineering and Clinical Application Branch of the Chinese Society of Biomedical Engineering, the chairman unit of the Zhongguancun Medical Device Industry Technology Innovation Alliance, a member company of the China Robot TOP10 Summit, and an innovative leading enterprise of Beijing's Biomedical Industry Leap Development Project (G20 Project). The company has received numerous national and provincial honors, including the second prize of the 2015 National Science and Technology Progress Award, and has a postdoctoral research workstation. TINAVI's core product, the TiRobot orthopedic surgical robot, assists doctors in precisely positioning implants or surgical instruments and can be widely used in spinal and trauma orthopedic surgeries with clinical accuracy within 1mm. It significantly reduces intraoperative radiation and improves surgical efficiency, simplifying complex surgeries, standardizing routine surgeries, making open surgeries minimally invasive, and equalizing medical resources. It empowers doctors, benefits patients, serves the "Healthy China" strategy, and supports China’s realization of self-reliance in high-end medical equipment. A promising future for smart orthopedics is on the horizon. As of mid-2021, the TiRobot orthopedic surgical robot has benefited over 15,000 patients across more than 100 medical institutions in over 20 provinces, cities, and autonomous regions in China.